| The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer B Adamo, GRR Ricciardi, A Ieni, T Franchina, C Fazzari, MV Sanò, ... Oncotarget 8 (44), 76974, 2017 | 49 | 2017 |
| Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience G Scandurra, RA Aiello, M Alì, E Taibi, MV Sanò, FM Todaro, R La Rocca, ... Future Oncology 8 (5), 609-615, 2012 | 14 | 2012 |
| Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer B Adamo, GRR Ricciardi, A Ieni, T Franchina, C Fazzari, MV Sanò, ... Oncotarget 10 (8), 917, 2019 | 6 | 2019 |
| Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials MV Sanò, F Martorana, G Lavenia, R Rossello, A Prestifilippo, S Sava, ... Expert Review of Anticancer Therapy 22 (4), 343-351, 2022 | 5 | 2022 |
| Abemaciclib-associated diarrhea: an exploratory analysis of real-life data V Gebbia, F Martorana, MV Sanò, MR Valerio, F Giotta, M Spada, ... Anticancer Research 43 (3), 1291-1299, 2023 | 3 | 2023 |
| A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy V Gebbia, F Martorana, G Scandurra, MR Valerio, S Cufari, P Vigneri, ... Journal of Oncology Pharmacy Practice 30 (5), 853-859, 2024 | 2 | 2024 |
| A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine F Martorana, G Scandurra, MR Valerio, S Cufari, P Vigneri, MV Sanò, ... Journal of Oncology Pharmacy Practice 30 (1), 173-181, 2024 | 2 | 2024 |
| Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review F Martorana, MV Sanò, MR Valerio, S Fogli, P Vigneri, R Danesi, ... Therapeutic Advances in Drug Safety 15, 20420986231224214, 2024 | 1 | 2024 |
| Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis E Collovà, A Ferzi, G Scandurra, G Aurilio, V Torri, L Porcu, MV Sanò, ... Tumori Journal 100 (4), 426-431, 2014 | 1 | 2014 |
| Why Do You Treat pCR Patient With Pertuzumab and Trastuzumab? MV Sanò, N Staropoli Clinical Breast Cancer, 2024 | | 2024 |
| statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story V Gebbia, MR Valerio, F Martorana, MV Sanò, P Vigneri Journal of Comparative Effectiveness Research 12 (6), e220212, 2023 | | 2023 |
| New potential therapeutic-sequence strategies of TDM1 in the revolutionary era of metastatic HER2-positive breast cancer treatment: A monocentric retrospective experience. MV Sanò, L Castellana, S Caffarelli, G Fallica, M Chiarenza, M Ali, ... Journal of Clinical Oncology 38 (15_suppl), e13014-e13014, 2020 | | 2020 |
| Salivary miRNA-210 involvement in medication-related osteonecrosis of the jaws. A Picone, A Marcianó, R Dimarco, E Miano, A Zacchia, MV Sanò, ... Journal of Clinical Oncology 35 (15_suppl), e23052-e23052, 2017 | | 2017 |
| Evaluation of quality of life in early breast cancer disease free survivors. a cross sectional survey D Aiello, S Patti, M Alì, MV Sanò, S Virgilio, E Taibi, VMG Di Leo, G Fallica, ... Annals of Oncology 27, iv74, 2016 | | 2016 |
| herapy P V Adamo, EA Bajardi, L Blasi, M Caruso, V Gebbia, V Leonardi, ... | | 2016 |
| 3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience M Caruso, G Castiglione, R Aiello, M Alí, M Chiarenza, R Dimarco, ... Future Oncology 11 (23), 3109-3112, 2015 | | 2015 |
| Adjuvant trastuzumab in the treatment of small HER2-positive tumors: A single institution experience. MV Sanò, E Taibi, M Ali, R Di Marco, A Zacchia, M Chiarenza, G Fallica, ... Journal of Clinical Oncology 32 (15_suppl), e11514-e11514, 2014 | | 2014 |
| Retrast: Retreatment after adjuvant trastuzumab—Our regional southern Italy experience. M Caruso, V Adamo, P Tralongo, D Giuffrida, V Gebbia, V Leonardi, ... Journal of Clinical Oncology 31 (15_suppl), e11526-e11526, 2013 | | 2013 |
| Efficacy and Safety of Trastuzumab in Small HER2 Positive Tumors. A Single Institution Experience MV Sano, E Taibi, M Alì, M Chiarenza, S Clementi, M Caruso, RA Aiello Annals of Oncology 23, ix104, 2012 | | 2012 |
| Different outcomes of cardiologic safety of trastuzumab in adjuvant or metastatic setting in patients with breast cancer: A single institution experience. G Scandurra, RA Aiello, E Taibi, MV Sanò, M Ali, G Fallica, M Chiarenza, ... Journal of Clinical Oncology 29 (15_suppl), e11028-e11028, 2011 | | 2011 |
